Cargando…

Tertiary lymphoid structure and decreased CD8(+) T cell infiltration in minimally invasive adenocarcinoma

Knowledge of the tumor microenvironment (TME) in patients with early lung cancer, especially in comparison with the matched adjacent tissues, remains lacking. To characterize TME of early-stage lung adenocarcinoma, we performed RNA-seq profiling on 58 pairs of minimally invasive adenocarcinoma (MIA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jin, Jiang, Dongbo, Zheng, Xiaoqi, Li, Wang, Zhao, Tian, Wang, Di, Yu, Huansha, Sun, Dongqing, Li, Ziyi, Zhang, Jian, Zhang, Zhe, Hou, Likun, Jiang, Gening, Fei, Ke, Zhang, Fan, Yang, Kun, Zhang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873609/
https://www.ncbi.nlm.nih.gov/pubmed/35243243
http://dx.doi.org/10.1016/j.isci.2022.103883
Descripción
Sumario:Knowledge of the tumor microenvironment (TME) in patients with early lung cancer, especially in comparison with the matched adjacent tissues, remains lacking. To characterize TME of early-stage lung adenocarcinoma, we performed RNA-seq profiling on 58 pairs of minimally invasive adenocarcinoma (MIA) tumors and matched adjacent normal tissues. MIA tumors exhibited an adaptive TME characterized by high CD4(+) T cell infiltration, high B-cell activation, and low CD8(+) T cell infiltration. The high expression of markers for B cells, activated CD4(+) T cells, and follicular helper T (Tfh) cells in bulk MIA samples and three independent single-cell RNA-seq datasets implied tertiary lymphoid structures (TLS) formation. Multiplex immunohistochemistry staining validated TLS formation and revealed an enrichment of follicular regulatory T cells (Tfr) in TLS follicles, which may explain the lower CD8(+) T cell infiltration and attenuated anti-tumor immunity in MIA. Our study demonstrates how integrating transcriptome and pathology characterize TME and elucidate potential mechanisms of tumor immune evasion.